Nasal Fluid Biomarker Kit for Non-Invasive Pet Cognitive Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional diagnostic methods for canine cognitive dysfunction are subjective, invasive, and lack objectivity, posing health risks to elderly companion animals.
Innovation Solution
A composition and kit using nasal fluid samples to measure the expression levels of UGT8 and BUD31 proteins or their genes for diagnosing cognitive dysfunction in companion animals, enabling non-invasive and convenient early diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional diagnostic methods (hematological tests, cytological tests, imaging examinations) are used, then diagnostic capability is achieved, but health risks and discomfort to elderly companion animals increase due to invasive procedures and anesthesia requirements
Solution Approach 1:
The patent uses nasal fluid as an intermediary sample type to diagnose cognitive dysfunction. Instead of directly accessing brain tissue or using invasive procedures, the method measures expression levels of specific proteins (UCH-L1, tau, beta-amyloid) in nasal fluid, which serves as a non-invasive mediator that reflects brain pathology. This resolves the contradiction by maintaining diagnostic capability while eliminating health risks associated with invasive procedures.
Solution Approach 2:
The patent replaces mechanical/invasive diagnostic procedures (biopsies, imaging examinations requiring anesthesia) with a biochemical measurement system. By using ELISA or other immunoassay methods to detect protein expression levels in nasal fluid, the system substitutes physical invasion with chemical detection, thereby maintaining diagnostic reliability while eliminating harm to the animal.
2Ease of operation
If conventional diagnostic methods (questionnaires, clinical examinations) are used, then diagnostic process is simple, but objectivity and reliability of diagnosis deteriorate due to subjective assessment
Solution Approach 1:
The patent replaces subjective mechanical assessment (questionnaires, clinical observations) with an objective biochemical measurement system. By quantifying protein expression levels (UCH-L1, tau, beta-amyloid) in nasal fluid using standardized immunoassay methods, the system transforms subjective diagnosis into objective numerical data, thereby improving measurement precision while maintaining ease of operation through non-invasive sampling.
Solution Approach 2:
The patent changes the diagnostic parameter from subjective behavioral observations to objective biochemical markers. Instead of relying on guardian assessments of symptoms, the method measures specific protein expression levels in nasal fluid, transforming the diagnostic basis from qualitative subjective evaluation to quantitative objective measurement, thereby resolving the contradiction between simplicity and objectivity.
3Measurement precision
If invasive diagnostic procedures (brain or spinal tissue biopsy) are used, then diagnostic accuracy is improved, but complexity and risk of the procedure increase
Solution Approach 1:
The patent uses nasal fluid as an accessible intermediary that provides diagnostic information about brain pathology without requiring direct access to the brain or spinal cord. The measurement of protein expression levels in this easily obtainable sample maintains diagnostic accuracy while dramatically simplifying the procedure and eliminating the need for complex surgical interventions.
Solution Approach 2:
The patent extracts the essential diagnostic information (protein expression levels indicating cognitive dysfunction) from the complex system of brain pathology and makes it measurable in a simple nasal fluid sample. By taking out the key diagnostic markers and detecting them in an accessible matrix, the method achieves high diagnostic accuracy without the complexity of tissue biopsy procedures.
Data Source
Figure 1A~1B
Figure 2A~2B
AI summary
The present disclosure relates to a composition for diagnosing cognitive dysfunction in a companion animal using a nasal fluid sample, and to a kit including the same.